Tango Therapeutics Inc. vs W.R. Berkley Corporation Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while W.R. Berkley Corporation Common Stock trades at $74.25 (market cap $27.30B). The key difference: W.R. Berkley Corporation Common Stock is far larger — about 7.3× Tango Therapeutics Inc.'s market cap, and W.R. Berkley Corporation Common Stock pays a 0.54% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and W.R. Berkley Corporation Common Stock for 0 Days on average.
| TNGX | WRB | |
|---|---|---|
Market Cap | $3.75B | $27.30B |
Volume | 9,619,106 | 2,293,079 |
Sector | Health | Financials |
52-Week High | $32.90 | $78.10 |
52-Week Low | $7.50 | $63.54 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.77B | $27.54B |
Dividend Yield | — | 0.54% |
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →W.R. Berkley Corporation is an insurance holding company that underwrites commercial property and casualty insurance and reinsurance through its Insurance and Reinsurance & Monoline Excess segments.
Read more on WRB →